Mumbai-based Lupin is a transnational pharmaceutical company producing and developing a wide range of branded and generic formulations, biotechnology products and APIs.
It deals with Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID and is a leader in Anti-TB and Cephalosporin segments.
Lupin is the 5th largest generics company in the US and the 3rd largest Indian pharmaceutical company by sales worldwide.
Pharma major Lupin said it was looking to launch over 2 dozen products in the US in the next fiscal. However, the company said other companies would be launching competing products as well, muting revenue growth.
MD Nilesh Gupta said the company would focus on "specialty drugs business in the US."
It has a portfolio of 128 generic drugs in the US.
Also Read:-
ONGC Mozambique deal under oil ministry scanner
Flipkart looking to consolidate Ekart services
Paytm to expand its travel business after selling 10 million tickets